Program
ruzasvir
Also written as “Ruzasvir”, “Bemnifosbuvir/Ruzasvir (BEM/RZR)” and “Ruzasvir 60 mg”.
Its studies are mostly in Hepatitis C, Chronic · Hepatitis C, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 50 open or running | phase 2since Jan 6, 2015 | Feb 27, 2014 | none ahead |
| Atea Pharmaceuticals | 20 open or running | phase 2since Jun 6, 2023 | Jun 6, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2014First study: phase 1 study in Hepatitis CNew to MerckMerck · NCT02076100 · 22 enrolled
- Jan 6, 2015Phase 2 study in Hepatitis CMerck · NCT02332707 · 443 enrolled
- Jan 25, 2016Phase 1 study in Hepatitis C, ChronicMerck · NCT02666352 · 24 enrolled
- Apr 29, 2016Phase 2 study in Hepatitis C, ChronicMerck · NCT02759315 · 160 enrolled
- Nov 2, 2016Phase 2 study in Hepatitis CMerck · NCT02956629 · 282 enrolled
- Jun 6, 2023Atea Pharmaceuticals's first study: phase 2 study in Hepatitis C, ChronicNew to Atea PharmaceuticalsAtea Pharmaceuticals · NCT05904470 · 275 enrolled · United States, Brazil, Canada and more
- Nov 19, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07272889 · 24 enrolled · Canada
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Nonstructural protein 5A inhibitor”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07272889Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Feb 17, 2026 | 24 |
| NCT05904470Hepatitis C, Chronic · United States, Brazil, Canada and more | 2 | Completed | Atea Pharmaceuticals | Dec 9, 2024 | 275 |
| NCT02956629Hepatitis C | 2 | Terminated | Merck | Dec 22, 2017 | 282 |
| NCT02759315Hepatitis C, Chronic | 2 | Terminated | Merck | Jul 27, 2017 | 160 |
| NCT02666352Hepatitis C, Chronic | 1 | Completed | Merck | Jan 16, 2017 | 24 |
| NCT02332707Hepatitis C | 2 | Completed | Merck | Sep 16, 2016 | 443 |
| NCT02076100Hepatitis C | 1 | Completed | Merck | Nov 15, 2015 | 22 |
How it is read
Names in the registry
- “Ruzasvir”, 5 entries
- “Bemnifosbuvir/Ruzasvir (BEM/RZR)”, 1 entry
- “Ruzasvir 60 mg”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 3 studies
- Hepatitis C, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.